Assistant Professor, Medicine, UCLA School of Medicine
Hematology
Dr. Bartosz Chmielowski, MD
|
|
Give Review
Bartosz Chmielowski works in the field of Hematology. He graduated from Medical College of Georgia. He received awards:"Top Doctors:LA Area" and "Top Doctors:Southern California". Bartosz Chmielowski is also published. He has 38 publications published. The lastest publication: "In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities.' He is registered with Medicare.
Publications
- A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
- A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV Melanoma.
- PD-1 blockade induces responses by inhibiting adaptive immune resistance.
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced Melanoma: a randomised dose-comparison cohort of a phase 1 trial.
- Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer.
- Insulin-like growth factor 1 receptor inhibitors: Where do we come from? What are we? Where are we going?
- The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
- Safety and tumor responses with lambrolizumab (anti-PD-1) in Melanoma.
- Multifunctional T-Cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy.
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
- Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors.
- Natural killer T cells in advanced Melanoma patients treated with tremelimumab.
- Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma.
- Survival in BRAF V600-mutant advanced Melanoma treated with vemurafenib.
- Single-institution, multidisciplinary experience with surgical resection of primary chest wall sarcomas.
- RAS mutations in cutaneous squamous-cell Carcinomas in patients treated with BRAF inhibitors.
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway.
- KIT as a therapeutic target in metastatic Melanoma.
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans.
- Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic Melanoma: results of a phase 1 clinical trial.
- The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
- Multicenter phase II study of matured dendritic cells pulsed with Melanoma cell line lysates in patients with advanced Melanoma.
- Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic Melanoma.
- CD40 expression by human melanocytic lesions and Melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.
- Differential sensitivity of Melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
- Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced Melanoma treated with tremelimumab.
- Do we need a different set of response assessment criteria for tumor immunotherapy?
- Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic Melanoma.
- Interferon alfa in the postsurgical management of high-risk Melanoma: is it worth it?
- The specific T-Cell response to antigenic peptides is influenced by bystander peptides.
- Presentation of antagonist peptides to naive CD4+ T Cells abrogates spatial reorganization of class II MHC peptide complexes on the surface of dendritic Cells.
- Altered selection of CD4+ T Cells by class II MHC bound with dominant and low abundance self-peptides.
- Mature CD4+ T Cells perceive a positively selecting class II MHC/peptide complex in the periphery.
- On the role of high- and low-abundance class II MHC-peptide complexes in the thymic positive selection of CD4(+) T Cells.
- In the normal repertoire of CD4+ T Cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities.
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Doctors:LA Area
- Top Doctors:Southern California
Education
-
UCLA Medical Center -
Medical College of Georgia -
Wroclaw Medical University
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1801067897 | |
| NPPES Provider LastName | CHMIELOWSKI | |
| NPPES Provider FirstName | BARTOSZ | |
| NPPES Provider ZIPCode | 900953000 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 194.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 6.7 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1801067897 |
| Last Name Of The Provider | CHMIELOWSKI |
| First Name Of The Provider | BARTOSZ |
| View All |
Similar Doctors
|
|
Seong H. Kim, NP |
|
|
Dr. Becky J. Miller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanchana S. Anand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David P. Masiello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amir Goldkorn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patricia A. Ganz, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mary M. Ichiuji, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol J. Hanna, MD |
|
|
Dr. Patrick Y. Chun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert D. Leibowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dennis J. Slamon, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Antoni B. Ribas, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David Shin, MD |
|
|
Dr. Levon Qasabian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew M. Denicola, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aryeh Edelist, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin I. Leach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Reva Kakkar, MD |
|
|
Dr. Hyung C. Suh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
William P. Sheridan |
|
|
Dr. Margaret K. Yu, MD |